Sigma Capital Management’s AstraZeneca AZN Stock Holding History

Sigma Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-230,000	Closed	-$14.9M	–	11
2014 Q1	$14.9M	Buy	230,000 +80,000	+53%	+$5.17M	0.76%	49
2013 Q4	$8.91M	Sell	150,000 -235,000	-61%	-$12.8M	0.5%	56
2013 Q3	$20M	Buy	+385,000	New	+$19.3M	0.84%	42

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MCM

Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sigma Capital Management's AZN Position: Q2 2014 in Review

Sigma Capital Management sold out of AstraZeneca (AZN) in Q2 2014, closing a stake of 230,000 shares — an estimated $14.9M sold.

Sigma Capital Management first reported a position in AZN in Q3 2013 and held it in 3 quarters. The position peaked at $20M in Q3 2013. 418 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

Sigma Capital Management reported no remaining AstraZeneca position as of Q2 2014 after selling out during the quarter.
Sigma Capital Management sold 230,000 AstraZeneca shares in Q2 2014, an estimated $14.9M.
Sigma Capital Management first reported a position in AstraZeneca in Q3 2013 and held it in 3 quarters.
Sigma Capital Management's AstraZeneca position peaked at $20M in Q3 2013.
418 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on Sigma Capital Management's 13F filing for Q2 2014.